Story perspectives

New Biomarker Study Links ctDNA to Cancer Treatment Outcomes

9/5/2025

46 6

Summary

Story summary

Myriad Genetics presented a study on its Precise MRD test for oligometastatic clear-cell renal cell carcinoma at the 2025 American Association for Cancer Research Annual Meeting.
The study found a correlation between circulating tumor DNA (ctDNA) levels and responses to metastasis-directed radiation therapy (MDT).
ctDNA negative patients maintained MDT for a median of 54 months, while ctDNA positive patients progressed to systemic therapy within 27 months.
The findings indicate ctDNA as a potential biomarker for MDT candidate identification.
Myriad plans to further investigate Precise MRD's effectiveness in renal cancer and other conditions.

1 of 1

Story summary

Myriad Genetics presented a study on its Precise MRD test for oligometastatic clear-cell renal cell carcinoma at the 2025 American Association for Cancer Research Annual Meeting.
The study found a correlation between circulating tumor DNA (ctDNA) levels and responses to metastasis-directed radiation therapy (MDT).
ctDNA negative patients maintained MDT for a median of 54 months, while ctDNA positive patients progressed to systemic therapy within 27 months.
The findings indicate ctDNA as a potential biomarker for MDT candidate identification.
Myriad plans to further investigate Precise MRD's effectiveness in renal cancer and other conditions.